Filament BioSolutions Inc. is developing and commercializing a portfolio of clinical nutrition products. We apply the principles of scientific rigor and evidence-based clinical development to establish efficacy and confirm safety of our products.
We are experienced biopharmaceutical executives and scientists. Our corporate partners include Ajinomoto, a global leader in the manufacturing and supply of amino acids. We also have academic partners at New York University, Massachusetts General Hospital, and University of California – San Francisco.
Our initial focus is on therapeutic areas that have a clear unmet need for clinical nutrition therapies. This includes supportive care oncology as well as urological and gastrointestinal disorders. Our bespoke development approach is driven by the optimal regulatory pathway for each product.
Thomas Cirrito Ph.D. is also a co-founder of Immunovent, a development stage biotechnology company developing a next-generation, non-invasive allergy diagnostic, and Biotagenics, a platform company that is developing therapeutics and diagnostics based on a proprietary database of clinical samples from patients with inflammatory bowel disease. Dr. Cirrito previously served as Vice President of Research and Development and Director of Business Development at Stemline Therapeutics (NASDAQ: STML) since March 2012. Dr. Cirrito joined Stemline in 2005 as the second full-time employee, and was responsible for business development, preclinical, intellectual property, manufacturing, analytical, and operations. Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously, he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group. Dr. Cirrito received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, Missouri). He currently serves on the Scientific and Business Advisory Board of the Alzheimer's Drug Discovery Foundation. He serves as an investor and mentor to early stage biotechnology and health care companies.
Bradley Theien MS MBA joined Filament from Pfizer, where he was part of the Strategy, Portfolio and Commercial Operations group and led a team that supported clinical and investment decisions for Pfizer’s Worldwide R&D organization. Prior to Pfizer, Mr. Theien was a managing consultant for bioStrategies Group, a life science consulting firm focused on developing commercial strategies for new and existing healthcare products and technologies. Mr. Theien also was a biopharmaceutical equity analyst at Prudential Securities where he covered several small-cap biotechnology companies. He has authored two papers on homing of T cells from the periphery into the CNS and previously researched neural mechanisms of taste-guided behavior. Mr. Theien received a MS in Biotechnology and an MBA from Northwestern University.
Kate Rochlin Ph.D. is a Co-Founder and Chief Scientific Officer of Immunovent, a development stage biotechnology company creating a next-generation, non-invasive allergy diagnostic. Her responsibilities include directing the research & development program, business development and management of the preclinical program. Dr. Rochlin completed her Ph.D. at Cornell University in New York City, where her work focused on muscular dystrophy and the role of RNA regulation in muscle-tendon attachment. Prior to this Dr. Rochlin worked at the University of Pennsylvania School of Medicine studying signaling in metastatic cancer. Dr. Rochlin earned her BA from the University of Pennsylvania.
Jason Rosenberg is a Co-Founder of Jibon Health Technologies, a Columbia University biotech start-up focused on medical technologies for developing countries that has won several international awards and accolades. Mr. Rosenberg also worked at FINCA, one of the largest microfinance institutions, supporting the creation of an impact fund for healthcare and solar technologies in their Social Enterprise and Financial Innovation department. He received a BS from University of Wisconsin – Madison.
Zeil Rosenberg MD MPH is VP of Medical Affairs at Admera Health, an advanced molecular diagnostics company, where he works on precision medicine and non-invasive cancer testing. His executive experience includes leadership positions in a wide range of business and clinical settings including CEO of a publicly traded medical nutrition company, Worldwide Medical Director for Immunization at Becton Dickinson (BD), and National Medical Director at the Children’s Health Fund. Dr. Rosenberg earned his MD from UCSF, MPH from Columbia and his BA from Stanford. He is a Specialty Fellow of the American Academy of Pediatrics and Fellow of the American College of Preventive Medicine and the New York Academy of Medicine. He served as AAS Science, Engineering and Diplomacy Fellow and is currently an adjunct faculty member at Columbia’s Mailman School of Public Health.
David S. Seres, MD, ScM, PNS, FASPEN has been a nutrition support practitioner for 27 years. He is Director of Medical Nutrition, Associate Clinical Ethicist, and Associate Professor of Medicine, Columbia University College of Physicians and Surgeons Institute of Human Nutrition, where he runs the Nutrition Support clinical consultation service, directs the medical school nutrition curriculum, and evaluates, designs, and runs clinical trials focused on nutrition. He is former Chair of Physician Certification for the National Board of Nutrition Support Certification, and of the Medical Practice Section of the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). There he serves on several policy and safety committees, and was recently elected as a Fellow, their highest honor. He is currently Chair Elect of the Medical Nutrition Council and member of the board of directors (ex officio) at the American Society of Nutrition, where he received their senior award for nutrition education. He has coauthored multiple safety guidelines, research studies, chapters, invited reviews, and op ed essays, and recently edited a new textbook. He appears frequently on the media advocating against dangerous consumer foods, supplements, and nutritional practices.
Elliot Goodman MD is a Pioneer in new techniques in endoluminal gastric surgery. He joined the medical staff of Beth Israel Medical Center in January, 2004. Previously, he was chief of bariatric surgery at Montefiore Medical Center. He is on the surgical faculty of the Albert Einstein College of Medicine. Before coming to New York, he was on the faculty of the New Jersey Medical School and was the Co-Director of the University Institute for the Surgery of Morbid Obesity. Dr. Goodman is an active member of the American Society of Bariatric Surgeons. His clinical interests include general and bariatric surgery. He has considerable research experience studying how immunosuppressive medications improve the success of organ transplants. Dr. Goodman received his undergraduate and medical school education at Cambridge University, and trained in general surgery at Maimonides Medical Center in Brooklyn. He is also a USA/Israel venture partner to GCV Life - a healthcare investment bank based in Mumbai, India.
FB-2710, an oral, proprietary formulation of an optimal analog of glutamine, is in development to delay the onset and decrease the severity of chemotherapy and radiation-induced Oral Mucositis.
Oral Mucositis is inflammation and damage of the oral mucosa as a result of chemotherapy and radiation. This painful and severe condition can lead to treatment dose reductions, serious infections, compromised nutrition, and higher rates of hospitalization. There is currently no FDA-approved drug to prevent or treat Oral Mucositis. Filament is initially focused on radiation-induced OM.
FB-4040 is a patented combination of citrates and anti-oxalates formulated to raise urine Citrate and pH.
This functional beverage was developed by a team of leading urologists for those that need to add citrate to their diet. FB-4040 is designed to be convenient and effective way to improve kidney and renal health/function for patients through a targeted and medically relevant nutritional regimen.
In 2016, Filament licensed the intellectual property for FB-4040 from New York University, Massachusetts General Hospital, and University of California, San Francisco.
FB-3100 is a patented amino acid combination with therapeutic potential as a supportive care agent.
In 2016, Filament licensed from Ajinomoto a portfolio of intellectual property covering FB-3100. Data from a pilot clinical study in gastric and colorectal cancer patients demonstrated a lower incidence and severity of several chemotherapy-related side effects.
FB-5402 is an optimized resistant starch with therapeutic potential for inflammatory gastro-intestinal conditions.
Filament is collaborating with leading ingredient manufacturers and Biotagenics, an early-stage microbiome company, to screen and optimize resistant starches using proprietary microbiome analysis and screening platforms. This research is focused on developing a nutrition-based therapy that will help patients suffering from Inflammatory Bowel Disease (IBD) through targeted modulation of gut bacteria composition and function.
Filament Biosolutions and Ajinomoto have entered into a broad collaboration to develop a portfolio of high quality, clinically-validated therapeutic nutrition products. Under the collaboration, Ajinomoto supplies amino acids used in a variety of Filament therapeutic products. Ajinomoto also supports Filament’s product and clinical activities through collaboration with its basic and clinical scientists, food technologists, and technical capabilities. As a component of this partnership; Ajinomoto has provided financing to Filament to accelerate the growth of the company and the development of its product portfolio.
Filament Biosolutions has entered into a strategic R&D partnership to explore the interface of clinical nutrition and the microbiome. This collaboration will develop an in-depth understanding of the impact of nutrition on the microbiome and role of the microbiome in regulating the body’s nutritional status. This research is expected to lead to the development of advanced diagnostics, therapeutics, and medical foods that will compliment both companies existing product platforms.
Filament is actively seeking innovative products and opportunities for partnering or in-licensing of therapeutic nutrition candidates that complement our existing product portfolio and infrastructure.
firstname.lastname@example.org to discuss partnership or licensing opportunities.
Filament BioSolutions Inc. is located in New York, NY. We can be reached via email@example.com.